Charles Schwab Investment Management Inc. lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free ...

We recently published a list of Top 10 Trending Stocks as AI Hype Fades. In this article, we are going to take a look at ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

J.P. Morgan analyst Brian Cheng maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) yesterday and set a price target ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital ...

OSCEOLA COUNTY, Fla. — The Osceola County Sheriff’s Office has arrested 26 suspects in a fentanyl trafficking bust that is ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...